Arbutus Biopharma Corp (ABUS): Results of Operations and Financial Condition
Arbutus Biopharma Corp (ABUS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026 Received first payment of approximately $178M from Moderna set
How this was made
The 30-second read
Why it matters
The most tradable elements are the disclosed cash receipt from Moderna and the stated expectation to return up to $230M to shareholders starting in Q3, alongside FDA Fast Track designation and Phase 2b trial design alignment for imdusiran.
Market read
Settlement cash and a planned capital return are immediate catalysts, while FDA alignment for imdusiran supports longer-dated clinical optionality.
What to watch
Repurchases are subject to board approval and may not occur in Q3; additionally, revenue remains small ($1.0M quarterly), so valuation support may be fragile without clearer clinical or commercialization milestones.
Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Operating results reflected lower collaboration and license revenue and a quarterly net loss, while research and development expense declined, cash and marketable securities increased modestly, and the Company received $178.4 million from the Moderna settlement in July 2026.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenueGAAP | $1.0 million | – | decrease of $9.7 million |
| Research and development expensesGAAP | $2.9 million | – | decrease of $2.6 million |
| General and administrative expensesGAAP | $3.9 million | – | – |
| Change in fair value of contingent considerationGAAP | 213 | – | – |
| Restructuring costsGAAP | — | – | – |
| Total operating expensesGAAP | 6,978 | – | – |
| Loss from operationsGAAP | (5,964) | – | – |
| Interest incomeGAAP | 842 | – | – |
| Interest expenseGAAP | (18) | – | – |
| Total other incomeGAAP | 821 | – | – |
| Net lossGAAP | $5.1 million | – | – |
| Basic net loss per common shareGAAP | loss of $0.03 per basic common share | – | – |
| Diluted net loss per common shareGAAP | loss of $0.03 per diluted common share | – | – |
| Weighted average number of common shares, basicGAAP | 197,470,724 | – | – |
| Weighted average number of common shares, dilutedGAAP | 197,470,724 | – | – |
| Cash, cash equivalents and marketable securitiesother | $92.6 million | – | – |
| Receivable from Genevant licenseGAAP | 179,373 | – | – |
| Net cash used in operating activitiesGAAP | (14,128) | – | – |
| Net cash provided by investing activitiesGAAP | 538 | – | – |
| Net cash provided by financing activitiesGAAP | 14,767 | – | – |
| Cash and cash equivalents, end of periodGAAP | 19,171 | – | – |
| Investments in marketable securitiesGAAP | 73,454 | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Collaborations and licensesTotal revenue declined primarily because the Company recognized all $9.6 million of previously deferred revenue upon conclusion of its strategic partnership with Qilu in June 2025. | $202 | – | – |
| License revenue from GenevantNo driver was provided. | $632 | – | – |
| Non-cash royalty revenueNo driver was provided. | $180 | – | – |
Q3 2026 outlook
- NoteArbutus expects to return capital to shareholders commencing in Q3 2026 through repurchases of up to approximately $230 million of the Company’s common shares.
- NoteThe Company anticipates the payment of a material dividend from Genevant in the third quarter of 2026.
- NoteThe Company intends to incorporate the FDA’s feedback into a final Phase 2b protocol.
Capital returns
- Arbutus expects to return capital to shareholders commencing in Q3 2026 through repurchases of up to approximately $230 million of the Company’s common shares.
- Repurchases may come in the form of a tender offer, including a modified “Dutch Auction” tender offer, open market purchases, accelerated share repurchases or other means.
- The specific form(s) of any such transaction(s) remains subject to the approval of the Company’s board of directors, and no assurance can be given that any such repurchase activity will occur in Q3 2026, or at all.
What drove it
- The $9.7 million decrease in revenue was due primarily to recognizing in the quarter ended June 30, 2025 all $9.6 million of previously deferred revenue upon conclusion of the Company’s strategic partnership with Qilu in June 2025.
- The $2.6 million decrease in research and development expenses was due primarily to cost savings from the Company’s decisions to reduce its workforce and discontinue in-house scientific research, as well as lower clinical trial costs as studies neared completion.
- The increase in general and administrative expenses was due primarily to higher stock compensation expenses.
- In May 2026, the Company reached alignment with the FDA on the design and safety parameters of a proposed Phase 2b clinical trial evaluating imdusiran for the treatment of cHBV.
- In July 2026, the Company and Genevant filed three international lawsuits against Pfizer, BioNTech and certain affiliates across 21 countries to enforce patents protecting the Company’s LNP technology.
Concerns
- Total revenue was $1.0 million, compared to $10.7 million for the same period in 2025.
- The Company reported a net loss of $5.1 million, compared to net income of $2.5 million for the quarter ended June 30, 2025.
- General and administrative expenses increased to $3.9 million from $3.3 million, primarily due to higher stock compensation expenses.
- The additional $1.3 billion Moderna payment is contingent upon an appellate ruling that 28 U.S.C. §1498 does not bar Arbutus’ and Genevant’s claims against Moderna for patent infringement, except as to doses characterized by the district court as having gone to U.S. government employees.
- No assurance can be given that any common-share repurchase activity will occur in Q3 2026, or at all.
What to watch
- The anticipated payment of a material dividend from Genevant in the third quarter of 2026.
- The form, board approval and execution of repurchases of up to approximately $230 million of common shares.
- Finalization of the imdusiran Phase 2b protocol incorporating FDA feedback.
- The contingent Moderna settlement payment and the patent-enforcement lawsuits against Pfizer and BioNTech.
- Progress in the imdusiran program, which the Company stated has achieved functional cure in 10 chronic hepatitis B patients to date.
Balance sheet and cash flow
- Cash, cash equivalents and investments in marketable securities were $92.6 million as of June 30, 2026, compared to $91.5 million as of December 31, 2025.
- On July 8, 2026, the Company received $178.4 million as its share of the Noncontingent Settlement Payment, which includes reimbursement of the Company’s litigation costs.
- Receivable from Genevant license was 179,373 as of June 30, 2026.
- During the six months ended June 30, 2026, the Company used $14.1 million in operating activities, which included one-time payments related to its restructuring efforts, and received $14.7 million of proceeds from the exercise of stock options.
- Accounts payable and accrued liabilities were 2,850 as of June 30, 2026, compared to 5,459 as of December 31, 2025.
- Liability related to sale of future royalties was 3,111 as of June 30, 2026, compared to 3,442 as of December 31, 2025.
- Contingent consideration was 8,817 as of June 30, 2026, compared to 8,395 as of December 31, 2025.
Analysis
Arbutus reported $1.0 million of total revenue for the quarter ended June 30, 2026, compared with $10.7 million in the same period in 2025. The Company attributed the $9.7 million decline primarily to the prior-year recognition of all $9.6 million of previously deferred revenue associated with the conclusion of the Qilu strategic partnership. The quarter included $202 of collaborations and licenses revenue, $632 of license revenue from Genevant, and $180 of non-cash royalty revenue, with the financial statements presented in thousands.
Expenses declined overall, led by research and development expense of $2.9 million versus $5.5 million. Management attributed the reduction to workforce and in-house research reductions and lower clinical trial costs as studies neared completion. General and administrative expense increased to $3.9 million from $3.3 million due primarily to higher stock compensation expenses. Total operating expenses were 6,978 versus 9,251, and the Company recorded a loss from operations of (5,964), compared with income from operations of 1,488.
The Company recorded a net loss of $5.1 million, or a loss of $0.03 per basic and diluted common share, compared with net income of $2.5 million, or income of $0.01 per basic and diluted common share. Cash, cash equivalents and marketable securities were $92.6 million as of June 30, 2026, compared with $91.5 million at December 31, 2025. For the six months ended June 30, 2026, net cash used in operating activities was (14,128), including one-time restructuring-related payments, while financing activities provided 14,767, including proceeds from stock option exercises.
The most consequential post-quarter financial development was the July 8 receipt of $178.4 million as Arbutus’ share of the Moderna Noncontingent Settlement Payment. Arbutus also stated that it owns approximately 16% of Genevant’s outstanding common equity and anticipates a material Genevant dividend in the third quarter of 2026. Separately, it expects to commence capital returns in Q3 2026 through repurchases of up to approximately $230 million of common shares, subject to board approval and with no assurance of execution.
Operationally, the FDA granted imdusiran Fast Track designation in April 2026, and the Company reached alignment with the FDA in May on the design and safety parameters of a proposed Phase 2b trial. The Company intends to incorporate the feedback into a final protocol. Investors will also be focused on the contingent $1.3 billion Moderna payment, the expected Genevant dividend, execution of the proposed share repurchases, and the three international LNP patent-enforcement lawsuits filed in July against Pfizer, BioNTech and certain affiliates across 21 countries.
Management, verbatim
This has been an exciting quarter for our imdusiran development program. In addition to obtaining Fast Track designation from the FDA on this promising drug candidate, which has achieved functional cure in 10 chronic hepatitis B patients to date, we reached alignment with the FDA on the design of our Phase 2b clinical trial. I would like to publicly congratulate our research and development team for their hard work and dedication in achieving these important milestones.
Lindsay Androski, President and CEO of Arbutus
Not in the filing
stated, not guessed- Gross profit and gross margin were not reported.
- Non-GAAP revenue, earnings, EPS, margins, or cash-flow measures were not reported.
- Prior-quarter revenue, expenses, operating income or loss, net income or loss, and EPS were not reported.
- Percentage year-over-year and quarter-over-quarter changes for the reported financial-statement line items were not reported.
- Free cash flow was not reported.
- Dividend amount was not reported.
- Financial guidance for revenue, gross margin, operating expenses, tax rate, earnings, EPS, or cash flow was not reported.
- Debt was not reported as a distinct line item.
- A previous-quarter outlook was not provided.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC 8-K (Item 2.02) with a press release covering Q2 2026 financials, the Moderna patent settlement cash receipt, international LNP patent enforcement, and FDA alignment for imdusiran Phase 2b in chronic hepatitis B.
Ticker impact
Arbutus reports Q2 2026 results and says it received $178.4M from the Moderna settlement, plus expects up to $230M in buybacks starting Q3.
Likely positive bias for ABUS into Q3 as traders price in settlement proceeds and the start of repurchases, tempered by ongoing clinical and revenue uncertainty.
The filing discloses a concrete cash receipt ($178.4M) and a specific shareholder return expectation (up to $230M repurchases starting Q3), both actionable catalysts, but it also shows continued net losses and modest revenue.
Market effects
Biopharma patent-litigation settlements and LNP technology enforcement remain a key risk-on driver for infectious-disease RNA/LNP platforms.
Limited direct regional spillover; primarily US-listed small-cap biotech sentiment.
International patent enforcement actions (21 countries) can influence perceived IP durability for LNP-based therapies globally.
Counterpoint
The settlement is noncontingent only for part of the total $950M, and the contingent $1.3B depends on an appellate outcome, so the upside may be overestimated.
Key entities
- issuerArbutus Biopharma Corporation
Clinical-stage biopharma focused on infectious disease; subject of the 8-K and recipient of Moderna settlement proceeds.
- counterpartyModerna
Paid Arbutus and Genevant $950M noncontingent in July 2026 and will pay additional contingent amounts after appellate ruling.
- licenseeGenevant Sciences
Exclusive licensee with Arbutus; Genevant receives settlement proceeds and is expected to pay a material dividend to Arbutus.
- regulatorU.S. Food and Drug Administration (FDA)
Granted Fast Track designation for imdusiran and aligned on Phase 2b trial design and safety parameters.
- counterpartyPfizer
Named in international patent enforcement lawsuits related to Arbutus LNP technology.
